摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-5-cyano-6-(methylthio)-4(3H)-pyrimidinethione | 111971-58-5

中文名称
——
中文别名
——
英文名称
2-amino-5-cyano-6-(methylthio)-4(3H)-pyrimidinethione
英文别名
2-amino-4-methylthio-5-cyano-1H-pyrimidine-6-thione;2-amino-4-methylthio-5-cyano-6(1H)-pyrimidinethione;2-amino-5-cyano-4-methylthio-1H-pyrimidine-6-thione;2-amino-4-methylsulfanyl-6-sulfanylidene-1H-pyrimidine-5-carbonitrile
2-amino-5-cyano-6-(methylthio)-4(3H)-pyrimidinethione化学式
CAS
111971-58-5
化学式
C6H6N4S2
mdl
MFCD00456310
分子量
198.272
InChiKey
HSXOIMUHFJUXIW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    273-275 °C (decomp)
  • 沸点:
    310.0±52.0 °C(Predicted)
  • 密度:
    1.57±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    132
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-amino-5-cyano-6-(methylthio)-4(3H)-pyrimidinethione氢氧化钾 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 反应 0.58h, 生成 2-amino-8-hydroxy-4-methylthiopyrido[3',2':4,5]thieno[2,3-d]pyrimidin-6(5H)-one
    参考文献:
    名称:
    Synthesis of substituted 4-hydroxy-1H-thieno[2,3-b;4,5-b′]dipyridin-2-ones
    摘要:
    Substituted 4-hydroxy-1 H-thieno[2,3-b;4,5-b']dipyridin-2-ones were prepared by the reactions of 3-cyanopyridine-2(1 H)-thiones with alkyl 4-chloroacetoacetates and by intramolecular cyclization of alkyl 4-(2-pyridylthio)acetoacetates or alkyl 3-(3-aminothieno[2,3-b]pyridin-2-yl)-3-oxopropionates under the action of bases.
    DOI:
    10.1007/bf02494687
  • 作为产物:
    描述:
    sodium 2-amino-4-methylthio-5-cyanopyrimidine-6-thiolate盐酸 作用下, 以 为溶剂, 以20%的产率得到2-amino-5-cyano-6-(methylthio)-4(3H)-pyrimidinethione
    参考文献:
    名称:
    核酸成分及其类似物:新型胞嘧啶硫代糖苷类似物的设计和合成。
    摘要:
    新型胞嘧啶4-硫代糖苷类似物的新类别的合成已首先完成。该策略的主要步骤是通过2-氰基-N-芳基乙酰胺与氰基碳酰亚胺二硫代硫酸钠的缩合反应合成嘧啶-4-硫代硫酸钠,然后与α-溴糖偶联以提供相应的胞嘧啶4-硫代糖苷类似物。还制备了游离的硫代糖苷。随后报道了该策略在制备其他有效的嘧啶硫代糖苷中的应用的研究。
    DOI:
    10.1080/15257770.2016.1231318
点击查看最新优质反应信息

文献信息

  • N-Cyanochloroacetamidine — A convenient reagent for the regioselective synthesis of fused diaminopyrimidines
    作者:Vasilii A Artyomov、Lyudmila A Rodinovskaya、Anatolii M Shestopalov、Viktor P Litvinov
    DOI:10.1016/0040-4020(95)00935-3
    日期:1996.1
    enaminocyanamidines form pyrimidine rings under acid or base catalysis forming fused diaminopyrimidines. According to this common scheme, functionally substituted thieno[3,2-d]pyrimidines, thiazolo[4,5-d]pyrimidines, pyrimido[4″,5″:4′,5′]thieno[3′,2′:4,5]thieno[3,2-d]pyrimidine, pyrido[3′,2′4,5]thieno(selenopheno)[3,2-d]pyrimidines, their hydrogenated analogues, and pyrimido-[4′,5′:4,5]thieno[2,3-d]pyrimidine were synthesized
    N-氰基氯乙酰胺与共轭的巯基(硒代)腈反应,生成区域选择性S(Se)烷基化产物,该产物随后可参与Thorpe反应。所得的烯氨基氰在酸或碱催化下形成嘧啶环,形成稠合的二氨基嘧啶。根据该通用方案,功能性取代的噻吩并[3,2- d ]嘧啶,噻唑并[4,5- d ]嘧啶,嘧啶并[4“,5”:4',5']噻吩并[3',2': 4,5] thieno [3,2- d ]嘧啶,吡啶基[3',2'4,5] thieno(硒代苯酚)[3,2- d ]嘧啶,它们的氢化类似物和嘧啶-[4',5 ′:4,5]噻吩并[2,3- d ]嘧啶。
  • 2-Bromo-1-arylethylidenemalononitriles — Convenient reagents for the regioselective synthesis of fused pyridines
    作者:Vasilii A. Artyomov、Vladimir L. Ivanov、Anatolii M. Shestopalov、Victor P. Litvinov
    DOI:10.1016/s0040-4020(97)00847-8
    日期:1997.9
    subsequently involved in the Thorpe reaction. Resulting enaminoacrylonitriles form pyridine ring under base catalysis yielding thienodipyridines. According to this common scheme, functionally substituted thieno[3,2-b]pyridines, thiazolo[4,5-b]pyridines, thieno[3,2-b:4,5-b]dipyridines, their hydrogenated analogues, and pyrido[2′,3′:4,5]thieno[2,3-d]pyrimidine were synthesized.
    2-溴-1-芳基乙叉基丙二腈与共轭硫代乙腈反应生成区域选择性S烷基化产物,该产物随后可参与Thorpe反应。所得的烯氨基丙烯腈在碱催化下形成吡啶环,产生噻吩并吡啶。根据该通用方案,功能上取代的噻吩并[3,2- b ]吡啶,噻唑并[4,5- b ]吡啶,噻吩并[3,2- b:4,5- b ]二吡啶,它们的氢化类似物和吡啶基合成了[2',3':4,5]噻吩并[2,3- d ]嘧啶。
  • P70S6 Kinase Modulators And Method Of Use
    申请人:Cheng Wei
    公开号:US20070208020A1
    公开(公告)日:2007-09-06
    The invention provides compounds and methods for inhibition of kinases, more specifically p70S6 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
    本发明提供了用于抑制激酶的化合物和方法,更具体地是p70S6激酶。本发明提供了用于调节蛋白激酶酶活性以调节细胞活动的化合物,例如增殖、分化、程序性细胞死亡、迁移、化学侵袭和代谢。本发明的化合物抑制、调节和/或调节与上述细胞活动相关的激酶受体信号转导途径,并且本发明包括含有这些化合物的组合物以及使用它们治疗激酶依赖性疾病和病况的方法。
  • P70S6 kinase modulators and method of use
    申请人:Exelixis, Inc.
    公开号:US07816353B2
    公开(公告)日:2010-10-19
    Compounds of formula III: wherein R5a, R3, X, Y, Q, R1a and R1b are as defined in the specification, pharmaceutically acceptable salts thereof, and methods of use thereof.
    公式III的化合物:其中R5a,R3,X,Y,Q,R1a和R1b的定义如规范所述,其药学上可接受的盐,以及其使用方法。
  • P70S6 Kinase Modulators and Method of Use
    申请人:Cheng Wei
    公开号:US20110021525A1
    公开(公告)日:2011-01-27
    The invention provides compounds and methods for inhibition of kinases, more specifically p70S6 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
    本发明提供了抑制激酶(更具体地说是p70S6激酶)的化合物和方法。本发明提供了用于调节蛋白激酶酶活性以调节细胞活动(如增殖、分化、程序性细胞死亡、迁移、化学入侵和代谢)的化合物。本发明的化合物抑制、调节和/或调节与上述细胞活动相关的激酶受体信号转导途径,并包括含有这些化合物的组合物和使用它们治疗激酶依赖性疾病和病况的方法。
查看更多